Works matching DE "CANCER chemotherapy"

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

    Published in:
    Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf075
    By:
    • Rippstein, Nicolas;
    • Zemmour, Christophe;
    • Rodrigues, Manuel;
    • Ray-Coquard, Isabelle;
    • Gladieff, Laurence;
    • Pautier, Patricia;
    • Frénel, Jean-Sébastien;
    • Costaz, Hélène;
    • Lebreton, Coriolan;
    • Pomel, Christophe;
    • Colombo, Pierre-Emmanuel;
    • Marchal, Frédéric;
    • Guillemet, Cécile;
    • Rouge, Thibault de la Motte;
    • Eberst, Lauriane;
    • Bosquet, Lise;
    • Deluche, Elise;
    • Sabatier, Renaud
    Publication type:
    Article
    21
    22

    Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

    Published in:
    Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf048
    By:
    • Ueno, Naoto T;
    • Cottone, Francesco;
    • Dunton, Kyle;
    • Jacot, William;
    • Yamashita, Toshinari;
    • Sohn, Joohyuk;
    • Tokunaga, Eriko;
    • Prat, Aleix;
    • Tsurutani, Junji;
    • Park, Yeon Hee;
    • Rugo, Hope S;
    • Xu, Binghe;
    • Cardoso, Fatima;
    • Mitri, Zahi;
    • Mahtani, Reshma;
    • Aguilar, Cecilia Orbegoso;
    • Xiao, Feng;
    • Harbeck, Nadia;
    • Cameron, David A;
    • Modi, Shanu
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Pericardial artery lymphoma in a patient with dermatomyositis: A case report.

    Published in:
    Modern Rheumatology Case Reports, 2025, v. 9, n. 1, p. 100, doi. 10.1093/mrcr/rxae065
    By:
    • Kei Hirose;
    • Takayuki Katsuyama;
    • Natsuki Kubota;
    • Yuya Terajima;
    • Kazuya Matsumoto;
    • Kenta Shidahara;
    • Takato Nakadoi;
    • Shoichi Nawachi;
    • Yu Katayama;
    • Yoshia Miyawaki;
    • Eri Katsuyama;
    • Mariko Narazaki-Takano;
    • Yoshinori Matsumoto;
    • Noboru Asada;
    • Ken-Ei Sada;
    • Jun Wada
    Publication type:
    Article
    33
    34
    35
    36
    37

    Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-60144-2
    By:
    • Ma, Jingsong;
    • Zhao, Jiabao;
    • Zhang, Chensong;
    • Tan, Jinshui;
    • Cheng, Ao;
    • Niu, Zhuo;
    • Lin, Zeyang;
    • Pan, Guangchao;
    • Chen, Chao;
    • Ding, Yang;
    • Zhong, Mengya;
    • Zhuang, Yifan;
    • Xiong, Yubo;
    • Zhou, Huiwen;
    • Zhou, Shengyi;
    • Xu, Meijuan;
    • Ye, Wenjie;
    • Li, Funan;
    • Song, Yongxi;
    • Wang, Zhenning
    Publication type:
    Article
    38
    39
    40

    PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 6, p. 1049, doi. 10.1007/s10147-025-02758-6
    By:
    • Matsumura, Noriomi;
    • Mandai, Masaki
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50